Abstract

OBJECTIVE:

Paraquat is widely used in the world, and all treatments for paraquat poisoning have been unsuccessful. Many patients have died of paraquat poisoning in developing countries. A novel anti-inflammation method was developed to treat severe paraquat-poisoned patients with >50% to <90% predictive mortality: initial pulse therapy with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone 20 mg/day until Pao2 was >11.5 kPa (80 mm Hg) and repeated pulse therapy with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 1 day), which was repeated if Pao2 was <8.64 kPa (60 mm Hg).

DESIGN:

Randomized controlled trial.

SETTING:

Academic medical center in Taiwan.

PATIENTS:

Twenty-three paraquat-poisoned patients with >50% and <90% predictive mortality assessed by plasma paraquat levels were prospectively and randomly assigned to the control and study groups at a proportion of 1:2.

INTERVENTIONS:

The control group received conventional therapy and the study group received the novel repeated pulse treatment with long-term steroid therapy.

MEASUREMENTS AND MAIN RESULTS:

We measured patient mortality during the study period. There was not a different distribution of basal variables between the two study groups. The mortality rate (85.7%, six of seven) of the control group was higher than that of the study group (31.3%, five of 16; p = .0272).

CONCLUSIONS:

The novel anti-inflammatory therapy reduces the mortality rate for patients with severe paraquat poisoning.